CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $3.6M, lower than 95% of all stocks globally
- PositionOperating margin is -3601.3%, lower than 95% of its Biotechnology peers (median -24.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.93BUSDvs all stocks (USD)
Revenue (TTM)
3.60MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.00xvs all stocks
52-Week Change
57.00%vs all stocks
Market Capitalization
3.93BUSDvs all stocks (USD)
Enterprise Value
3.31BUSDvs all stocks (USD)
Forward P/E
-10.24xvs Biotechnology peers
Price to Book (MRQ)
4.77xvs Biotechnology peers
Enterprise to Revenue
919.04xvs Biotechnology peers
Enterprise to EBITDA
-6.30xvs Biotechnology peers
Gross Margin
97.42%vs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-3601.30%vs Biotechnology peers
Return on Assets (TTM)
-29.15%vs Biotechnology peers
Return on Equity (TTM)
-54.93%vs Biotechnology peers
Revenue (TTM)
3.60MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0200USDUpdated Aug 27, 2026Gross Profit (TTM)
-397.21MUSDvs all stocks (USD)
EBITDA (TTM)
-526.06MUSDvs all stocks (USD)
Net Income (TTM)
-511.45MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-434.04MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-268.53MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-555.34MUSDvs all stocks (USD)
Pre-tax Income
-512.44MUSDFY2025 · Dec 31, 2025Income Tax Expense
102.00KUSDFY2025 · Dec 31, 2025Net Income
-512.54MUSDFY2025 · Dec 31, 2025EBIT
-555.34MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-540.53MUSDFY2025 · Dec 31, 2025Research & Development
418.78MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
136.56MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
42.90MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-512.54MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-402.27MUSDFY2025 · Dec 31, 2025Free Cash Flow
-411.77MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
208.43MUSDFY2025 · Dec 31, 2025Income Tax Paid
46.00KUSDFY2025 · Dec 31, 2025Interest Paid
720.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-512.54MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
14.81MUSDFY2025 · Dec 31, 2025Stock-based Compensation
99.63MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-4.40MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-7.52MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
7.74MUSDFY2025 · Dec 31, 2025Capital Expenditures
-9.50MUSDFY2025 · Dec 31, 2025Purchase of Investments
-441.26MUSDFY2025 · Dec 31, 2025Sale of Investments
706.05MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
255.28MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-8.17MUSDFY2025 · Dec 31, 2025Other Financing Charges
-324.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
180.76MUSDFY2025 · Dec 31, 2025Shares Outstanding
159.76MSharesUpdated Aug 27, 2026Float Shares
155.08MSharesUpdated Aug 27, 2026Shares Short
17.96MSharesUpdated Aug 27, 2026Short Ratio
10.78daysvs all stocks
Short % of Shares Outstanding
11.85%vs all stocks
% Held by Insiders
9.09%vs all stocks
% Held by Institutions
101.33%vs all stocks
Total Cash (MRQ)
710.47MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.45USDUpdated Aug 27, 2026Total Debt (MRQ)
37.69MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0451xvs Biotechnology peers
Current Ratio (MRQ)
8.37xvs Biotechnology peers
Book Value per Share (MRQ)
5.23USDUpdated Aug 27, 2026Total Assets
1.14BUSDvs all stocks (USD)
Total Current Assets
900.66MUSDFY2025 · Dec 31, 2025Total Liabilities
131.09MUSDFY2025 · Dec 31, 2025Total Non-current Assets
244.20MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
32.74MUSDFY2025 · Dec 31, 2025Total Current Liabilities
98.35MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
205.33MUSDFY2025 · Dec 31, 2025Other Short-term Investments
662.55MUSDFY2025 · Dec 31, 2025Accounts Receivable
2.18MUSDFY2025 · Dec 31, 2025Accounts Payable
3.33MUSDFY2025 · Dec 31, 2025Short-term Debt
9.55MUSDFY2025 · Dec 31, 2025Deferred Revenue
21.10MUSDFY2025 · Dec 31, 2025Long-term Debt
27.21MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
5.53MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.89MUSDFY2025 · Dec 31, 2025Retained Earnings
-2.05BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.01BUSDvs all stocks (USD)
52-Week Low
12.58USDUpdated Aug 27, 202652-Week High
27.30USDUpdated Aug 27, 202652-Week Change
57.00%vs all stocks
Beta
1.00xvs all stocks
50-Day MA
24.39USDUpdated Aug 27, 2026200-Day MA
20.51USDUpdated Aug 27, 2026Avg 10-Day Volume
1.10MSharesUpdated Aug 27, 2026Avg 30-Day Volume
1.39MSharesUpdated Aug 27, 2026Diluted EPS (TTM)
-2.93USDUpdated Aug 27, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -3601.3%, lower than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: -36.01Industry median: -0.24Industry P5: -33.54Peers compared: 194
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.97Profit Margin: 0.00
Financial Health
Altman Z-Score 14.71: safe zoneNotable
Altman Z-Score: 14.71
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $3.6M, lower than 95% of all stocks globallySignificant
Revenue (USD): 3,604,000Global P5: 32,166,921.735
Levered free cash flow is -$268.53M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -268,527,872Global P5: -209,187,555.994
Market cap is $3.93B, above the global median of $1.18BNotable
Market cap (USD): 3,927,450,691Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Livzon Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Xiamen Amoytop Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Duality Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Huahai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Catalyst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Arcus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Apeloa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ideaya Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Irhythm Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Zhejiang Hisun Biomaterials Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
HBL Engineering Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Olaplex Holdings, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity